momelotinib - Robuta Search

https://www.mayo.edu/research/clinical-trials/cls-20192984 A Study Using Momelotinib in Transfusion-Dependent Adults with Primary Myelofibrosis,... Learn more about services at Mayo Clinic. a study using momelotinib https://www.mdanderson.org/newsroom/targeted-therapy-momelotinib-provides-significant-symptom-and-anemia.h00-159615489.html Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with... Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the... targeted therapy https://www.cancer.gov/about-cancer/treatment/drugs/momelotinib-dihydrochloride-monohydrate Momelotinib Dihydrochloride Monohydrate - NCI This page contains brief information about momelotinib dihydrochloride monohydrate and a collection of links to more information about the use of this drug,... momelotinib dihydrochloride monohydrate nci https://www.businesswire.com/news/home/20220617005035/en/Sierra-Oncology-Announces-Submission-of-New-Drug-Application-for-Momelotinib-to-US-Food-Drug-Administration Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug... Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announc... new drug application https://www.svb.com/news/client-news/sierra-oncology-obtains-debt-facility-from-silicon-valley-bank-to-acquire-and-advance-momelotinib/ Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib https://www.pharmaceutical-technology.com/data-insights/momelotinib-dihydrochloride-gsk-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ Momelotinib dihydrochloride by GSK for Relapsed Acute Myeloid Leukemia: Likelihood of Approval Dec 29, 2024 - Momelotinib dihydrochloride is under clinical development by GSK and currently in Phase II for Relapsed Acute Myeloid Leukemia. acute myeloid leukemia momelotinib dihydrochloride https://www.biospace.com/sierra-announces-momelotinib-granted-fda-fast-track-designation Sierra Announces Momelotinib Granted FDA Fast Track Designation - BioSpace Jun 6, 2019 - Sierra Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2 and ACVR1... fda fast track sierra announces momelotinib granted https://www.gsk.com/en-gb/media/press-releases/gsk-announces-extension-of-fda-review-period-for-momelotinib/ GSK announces extension of FDA review period for momelotinib | GSK GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review. gsk announces extension fda review https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-accepts-marketing-authorisation-application-for-momelotinib-for-the-treatment-of-myelofibrosis/ European Medicines Agency accepts marketing authorisation application for momelotinib for the... Application includes data from key phase III trials, including the pivotal MOMENTUM trial. european medicines agency marketing authorisation accepts application momelotinib https://www.mayo.edu/research/clinical-trials/cls-20111479 Long-term Safety And Efficacy Of Momelotinib In Subjects With Primary Myelofibrosis,... Learn more about services at Mayo Clinic. long term https://www.cancerresearchuk.org/about-cancer/treatment/drugs/momelotinib Momelotinib | Cancer information | Cancer Research UK Momelotinib is a treatment for intermediate 2 or high risk myelofibrosis. Find out about possible side effects and other important information. cancer information momelotinib research uk https://www.mckesson.com/about-us/newsroom/press-releases/2023/ojjaara-fda-approved-treatment-myelofibrosis-available-biologics-by-mckesson/ OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia,... Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by GSK as a specialty pharmacy provider for... https://www.gsk.com/en-gb/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/ Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for... Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. in the us first and only https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-submission-for-momelotinib-for-the-treatment-of-myelofibrosis-accepted-for-review-by-japanese-regulator/ GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by... Submission included data from trials addressing clinical manifestations of myelofibrosis - splenomegaly, constitutional symptoms and anaemia regulatory submission the treatment